vs
Prestige Consumer Healthcare Inc.（PBH）与GIBRALTAR INDUSTRIES, INC.（ROCK）财务数据对比。点击上方公司名可切换其他公司
Prestige Consumer Healthcare Inc.的季度营收约是GIBRALTAR INDUSTRIES, INC.的1.3倍（$283.4M vs $225.0M），GIBRALTAR INDUSTRIES, INC.同比增速更快（24.9% vs -2.4%），Prestige Consumer Healthcare Inc.自由现金流更多（$75.3M vs $26.2M），过去两年Prestige Consumer Healthcare Inc.的营收复合增速更高（1.2% vs -12.3%）
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
直布罗陀工业公司是专业建筑、基础设施及可再生能源产品制造商与分销商，主营通风系统、屋面配件、太阳能安装支架、园林景观产品等，主要服务北美地区住宅、商业建筑及清洁能源市场，专注提供创新可持续的客户解决方案。
PBH vs ROCK — 直观对比
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $283.4M | $225.0M |
| 净利润 | $46.7M | — |
| 毛利率 | 55.5% | 25.3% |
| 营业利润率 | 29.1% | 7.9% |
| 净利率 | 16.5% | — |
| 营收同比 | -2.4% | 24.9% |
| 净利润同比 | -23.5% | — |
| 每股收益（稀释后） | $0.97 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $283.4M | $225.0M | ||
| Q3 25 | $274.1M | $310.9M | ||
| Q2 25 | $249.5M | $309.5M | ||
| Q1 25 | $296.5M | $290.0M | ||
| Q4 24 | $290.3M | $180.1M | ||
| Q3 24 | $283.8M | $277.1M | ||
| Q2 24 | $267.1M | $273.6M | ||
| Q1 24 | $277.0M | $292.5M |
| Q4 25 | $46.7M | — | ||
| Q3 25 | $42.2M | $-89.1M | ||
| Q2 25 | $47.5M | $26.0M | ||
| Q1 25 | $50.1M | $21.1M | ||
| Q4 24 | $61.0M | — | ||
| Q3 24 | $54.4M | $34.0M | ||
| Q2 24 | $49.1M | $32.2M | ||
| Q1 24 | $49.5M | $24.9M |
| Q4 25 | 55.5% | 25.3% | ||
| Q3 25 | 55.3% | 26.6% | ||
| Q2 25 | 56.2% | 28.4% | ||
| Q1 25 | 57.3% | 26.8% | ||
| Q4 24 | 55.5% | 29.0% | ||
| Q3 24 | 55.5% | 29.4% | ||
| Q2 24 | 54.7% | 30.5% | ||
| Q1 24 | 54.8% | 28.9% |
| Q4 25 | 29.1% | 7.9% | ||
| Q3 25 | 29.1% | 12.8% | ||
| Q2 25 | 28.8% | 12.8% | ||
| Q1 25 | 29.8% | 8.8% | ||
| Q4 24 | 31.7% | 13.3% | ||
| Q3 24 | 29.7% | 15.6% | ||
| Q2 24 | 27.0% | 14.9% | ||
| Q1 24 | 29.7% | 10.8% |
| Q4 25 | 16.5% | — | ||
| Q3 25 | 15.4% | -28.6% | ||
| Q2 25 | 19.0% | 8.4% | ||
| Q1 25 | 16.9% | 7.3% | ||
| Q4 24 | 21.0% | — | ||
| Q3 24 | 19.2% | 12.3% | ||
| Q2 24 | 18.4% | 11.8% | ||
| Q1 24 | 17.9% | 8.5% |
| Q4 25 | $0.97 | — | ||
| Q3 25 | $0.86 | $-2.98 | ||
| Q2 25 | $0.95 | $0.87 | ||
| Q1 25 | $1.00 | — | ||
| Q4 24 | $1.22 | — | ||
| Q3 24 | $1.09 | $1.11 | ||
| Q2 24 | $0.98 | $1.05 | ||
| Q1 24 | $0.98 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $62.4M | $115.7M |
| 总债务越低越好 | $1.0B | $0 |
| 股东权益账面价值 | $1.8B | $950.4M |
| 总资产 | $3.5B | $1.4B |
| 负债/权益比越低杠杆越低 | 0.56× | 0.00× |
8季度趋势，按日历期对齐
| Q4 25 | $62.4M | $115.7M | ||
| Q3 25 | $119.1M | $89.4M | ||
| Q2 25 | $139.5M | $43.3M | ||
| Q1 25 | $97.9M | $25.1M | ||
| Q4 24 | $50.9M | $269.5M | ||
| Q3 24 | $51.5M | $228.9M | ||
| Q2 24 | $34.3M | $179.1M | ||
| Q1 24 | $46.5M | $146.7M |
| Q4 25 | $1.0B | $0 | ||
| Q3 25 | $993.1M | $0 | ||
| Q2 25 | $992.7M | $0 | ||
| Q1 25 | $992.4M | $0 | ||
| Q4 24 | $992.0M | $0 | ||
| Q3 24 | $1.1B | $0 | ||
| Q2 24 | $1.1B | $0 | ||
| Q1 24 | $1.1B | $0 |
| Q4 25 | $1.8B | $950.4M | ||
| Q3 25 | $1.8B | $951.8M | ||
| Q2 25 | $1.9B | $1.0B | ||
| Q1 25 | $1.8B | $1.0B | ||
| Q4 24 | $1.8B | $1.0B | ||
| Q3 24 | $1.7B | $1.0B | ||
| Q2 24 | $1.7B | $975.7M | ||
| Q1 24 | $1.7B | $940.2M |
| Q4 25 | $3.5B | $1.4B | ||
| Q3 25 | $3.4B | $1.4B | ||
| Q2 25 | $3.4B | $1.5B | ||
| Q1 25 | $3.4B | $1.4B | ||
| Q4 24 | $3.3B | $1.4B | ||
| Q3 24 | $3.3B | $1.4B | ||
| Q2 24 | $3.3B | $1.4B | ||
| Q1 24 | $3.3B | $1.3B |
| Q4 25 | 0.56× | 0.00× | ||
| Q3 25 | 0.54× | 0.00× | ||
| Q2 25 | 0.54× | 0.00× | ||
| Q1 25 | 0.54× | 0.00× | ||
| Q4 24 | 0.55× | 0.00× | ||
| Q3 24 | 0.61× | 0.00× | ||
| Q2 24 | 0.65× | 0.00× | ||
| Q1 24 | 0.68× | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $78.3M | $35.5M |
| 自由现金流经营现金流 - 资本支出 | $75.3M | $26.2M |
| 自由现金流率自由现金流/营收 | 26.6% | 11.7% |
| 资本支出强度资本支出/营收 | 1.1% | 4.1% |
| 现金转化率经营现金流/净利润 | 1.68× | — |
| 过去12个月自由现金流最近4个季度 | $267.2M | $120.6M |
8季度趋势，按日历期对齐
| Q4 25 | $78.3M | $35.5M | ||
| Q3 25 | $57.5M | $73.0M | ||
| Q2 25 | $79.0M | $44.9M | ||
| Q1 25 | $61.8M | $13.7M | ||
| Q4 24 | $65.1M | $19.9M | ||
| Q3 24 | $69.8M | $64.7M | ||
| Q2 24 | $54.8M | $36.5M | ||
| Q1 24 | $66.9M | $53.2M |
| Q4 25 | $75.3M | $26.2M | ||
| Q3 25 | $55.4M | $64.8M | ||
| Q2 25 | $78.2M | $27.3M | ||
| Q1 25 | $58.4M | $2.3M | ||
| Q4 24 | $63.5M | $14.1M | ||
| Q3 24 | $67.8M | $60.5M | ||
| Q2 24 | $53.6M | $33.5M | ||
| Q1 24 | $63.8M | $48.8M |
| Q4 25 | 26.6% | 11.7% | ||
| Q3 25 | 20.2% | 20.8% | ||
| Q2 25 | 31.3% | 8.8% | ||
| Q1 25 | 19.7% | 0.8% | ||
| Q4 24 | 21.9% | 7.8% | ||
| Q3 24 | 23.9% | 21.8% | ||
| Q2 24 | 20.1% | 12.2% | ||
| Q1 24 | 23.0% | 16.7% |
| Q4 25 | 1.1% | 4.1% | ||
| Q3 25 | 0.8% | 2.6% | ||
| Q2 25 | 0.3% | 5.7% | ||
| Q1 25 | 1.2% | 3.9% | ||
| Q4 24 | 0.5% | 3.3% | ||
| Q3 24 | 0.7% | 1.5% | ||
| Q2 24 | 0.4% | 1.1% | ||
| Q1 24 | 1.1% | 1.5% |
| Q4 25 | 1.68× | — | ||
| Q3 25 | 1.36× | — | ||
| Q2 25 | 1.66× | 1.73× | ||
| Q1 25 | 1.23× | 0.65× | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | 1.28× | 1.90× | ||
| Q2 24 | 1.12× | 1.13× | ||
| Q1 24 | 1.35× | 2.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
ROCK
| Transferred At Point In Time | $183.5M | 82% |
| Infrastructure | $22.5M | 10% |
| Other | $18.9M | 8% |
